Major Pharmaceutical Markets of the Middle East

An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE

Publication Date	April 2006
Publisher	URCH Publishing
Product Type	Report
Pages	100
ISBN Number	954698150
Product Code	URC00016

Price

£799.00
approximately: $1,411 | €1,013

PDF immediate delivery

PRINT £850 ($1,501 | €1,078)

Order above formats by FAX

Summary

A a comprehensive report providing extensive coverage of one of the strongest emerging markets. Through quality analysis and forecasts, this unique report will allow you to identify market trends and growth potential opportunities.

The report provides the necessary background information for a firm to operate in the region.

Chapter summaries:

Chapter 1: covers the main characteristics of the Middle Eastern market through a Political, Economic, Social and Technological (PEST) analysis, plus insight into the tax environment and Free-Trade Agreements in place or being negotiated.

Chapter 2: reports on the Intellectual Property Rights environment of each of the countries covered.

Chapter 3: provides a overview of the regional pharmaceutical market, and includes data on consumption, production, imports, exports, as well as market forecasts.

The other chapters are in-depth per-country market studies.

Country coverage

Egypt, the largest pharmaceutical market of the region
Israel, home to the world's largest generic drug company
Jordan, the leading Arab pharmaceutical exporter
Lebanon, an almost exclusive import market
Saudi Arabia, the largest market of the Gulf
The United Arab Emirates, among the highest-priced markets in the region

Five key findings

The Middle East market has achieved impressive growth to reach $8bn worth in 2005. The regional pharmaceutical Combined Annual Growth Rate (CAGR) between 1999-2003 was second only to Southeast Asia and China.
The Middle East is a high-import market. Israel, Jordan, Saudi Arabia and Lebanon import respectively 60%, 70%, 80% and 94% of their pharmaceutical needs.
Local manufacturing capabilities are constrained to generics.
A high acceptance of Western medicines is present
Generics have a low market penetration as most countries apart from Egypt are considered brand-name countries.

What you can learn from this report

Which multinationals have invested in the Middle East
Who are the leading local pharmaceutical manufacturers and distributors
What are the trends in the pharmaceutical market and import and export sizes
How Intellectual Property Rights and patents are the most conflictual regional issue
Which countries have implemented health insurance and the likely impact on growth
What type of demand and supplyside cost controls are in place

Reasons to purchase the report

Five-year projected sales figure to enable proprietary forecasting
Detailed Political, Economic, Social and Technological (PEST) analysis providing thorough regional and country background
Extensive list of local contacts to facilitate finding a potential business partner
Thorough review of country pharmaceutical markets using latest available data
Researched by a native speaker using primary and secondary data

Content

Chapter 1: Characteristics of the Middle Eastern Pharmaceutical Market
- Political, economic, social and technological (PEST) analysis
- Political factors
- Economic factors
- Social factors
- Technological factors
- Free trade agreements
- Euro-Mediterranean Free Trade Area (EU-MEFTA)
- US-MEFTA (Middle East Free Trade Agreements)
- Gulf Cooperation Council (GCC)
- Taxation
- Egypt
- Israel
- Jordan
- Lebanon
- Saudi Arabia
- United Arab Emirates
Chapter 2: Intellectual Property Rights
- Trade-related Aspects of Intellectual Property Rights (TRIPS)
- Egypt
- Israel
- Jordan
- Lebanon
- Saudi Arabia
- United Arab Emirates
Chapter 3: Overview of the Middle Eastern Pharmaceutical Market
- Healthcare overview
- Pharmaceutical consumption
- Domestic production
- Imports
- Market forecast
Chapter 4: Egypt
- The healthcare structure
- The pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Public tenders
- Patient co-payment
- Generic substitution
- Leading companies
Chapter 5: Israel
- The healthcare structure
- The pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Prescribing limitations
- Generic substitution
- Patient co-payment
- Leading companies
Chapter 6: Jordan
- The healthcare structure
- The pharmaceutical market
- Market figures
- Point of interest: medical tourism
- Drug pricing and reimbursement
- Distributio
- Cost controls
- Co-payment
- Public-sector procurement
- Leading companies
Chapter 7: Lebanon
- The healthcare structure
- Point of interest: fraud
- The pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Public procurement
- National Drugs Office
- Patient co-payment
- Leading companies
Chapter 8: Saudi Arabia
- The healthcare structure
- Pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Private health insurance provision
- 'Dollarisation'
- Gulf Cooperation Council bulk buying
- Leading companies
Chapter 9: United Arab Emirates
- The healthcare structure
- Pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Bulk buying
- Co-payment
- Leading companies
Appendix
- Abbreviations
- Useful contacts
- Egypt
- Israel
- Jordan
- Lebanon
- Saudi Arabia
- United Arab Emirates
- Selected bibliography
List of Figures
- Figure 3.1 Projected market sizes for Egypt, Saudi Arabia and Israel
- Figure 3.2 Projected market sizes for the UAE, Lebanon and Jordan
- Figure 4.1 Exchange rate fluctuations (Egyptian pounds to the US dollar), 1997-2005
- Figure 5.1 Drug purchasers by share, 2001
- Figure 6.1 Jordan's sources of healthcare funds
- Figure 6.2 Jordan's national health expenditure, by healthcare provider
- Figure 7.1 Institutional framework of Lebanon's pharmaceutical sector
- Figure 9.1 Purchasers of pharmaceuticals in the public sector
List of Tables
- Table 1.1 Regional PEST factors affecting the pharmaceutical industry in the Middle East
- Table 2.1 Estimates of intellectual property losses inflicted on PhRMA members, 2004
- Table 3.1 Health indicators, 2003
- Table 3.2 Pharmaceutical market sizes in the Middle East, 2003
- Table 3.3 Annual per capita drug consumption figures in the Middle East, 2001
- Table 3.4 Largest local pharmaceutical manufacturers in the Middle East 1
- Table 3.5 Competitiveness of Middle Eastern pharmaceutical markets
- Table 3.6 Pharmaceutical imports and exports in the Middle East, 2003
- Table 4.1 Egypt's healthcare spending
- Table 4.2 Egypt's health and government budgets
- Table 4.3 Consumer expenditure on health goods and medical services (LEm)
- Table 4.4 OTC sales (LEm)
- Table 4.5 Egypt's average annual patient co-payment (Egyptian pounds)
- Table 4.6 Egypt's top 10 pharmaceutical companies, by revenue, 2001
- Table 4.7 Egypt's top 10 pharmaceutical products, by revenue, 2001
- Table 4.8 PEST factors affecting Egypt's pharmaceutical industry
- Table 5.1 Israel's healthcare expenditure
- Table 5.2 Israel's pharmaceutical market, at retail prices
- Table 5.3 Israel's consumer expenditure on health goods and medical services
- Table 5.4 Israel's pharmaceutical exports and imports
- Table 5.5 Israel's non-prescription pharmaceutical market, at retail prices
- Table 5.6 Retail sales of OTC healthcare in Israel
- Table 5.7 Co-payments for medicines by sick fund in Israel
- Table 5.8 Teva's sales and net income
- Table 5.9 PEST factors affecting Israel's pharmaceutical industry
- Table 6.1 Jordan's health insurance coverage
- Table 6.2 Breakdown of Jordan's public health spending
- Table 6.3 Jordan's Ministry of Health budgets, 2000-04 (JDm)
- Table 6.4 Jordan's health insurance budget, 2000-02 (JDm)
- Table 6.5 Admission costs for Jordan's public hospitals
- Table 6.6 Dar Al Dawa financials
- Table 6.7 PEST factors affecting Jordan's pharmaceutical industry
- Table 7.1 Lebanon's pharmaceutical market size and imports
- Table 7.2 Co-payments by insurer, in Lebanon
- Table 7.3 Hospital co-payments by insurer, in Lebanon
- Table 7.4 Lebanon's pharmaceutical production and exports
- Table 7.5 PEST factors affecting Lebanon's pharmaceutical industry
- Table 8.1 Saudi health-sector statistics, 2003
- Table 8.2 Saudi healthcare spending
- Table 8.3 Saudi consumer expenditure on health goods and services
- Table 8.4 The Saudi private pharmaceutical market
- Table 8.5 Saudi pharmaceutical imports (SRm)
- Table 8.6 Saudi retail sales of OTC healthcare
- Table 8.7 SPIMACO sales and profits, 2003 and 2004
- Table 8.8 Tabuk's turnover
- Table 8.9 Market share estimates for the Saudi private market, 2005
- Table 8.10 Sales estimates for leading products in the Saudi private market, 2005
- Table 8.11 Estimates of leading products by units in the Saudi private market, 2005
- Table 8.12 PEST factors affecting the Saudi pharmaceutical industry
- Table 9.1 Dubai's trade in pharmaceutical products
- Table 9.2 Revenue of Drug Control Department by category (in AED)
- Table 9.3 Julphar sales and profits
- Table 9.4 PEST factors affecting the pharmaceutical industry in the UAE